In Anticipation Of Medical Marijuana Legalization, Cannabis Science Adds Four Attorneys To Its New Policy Advisory Board, All Are Experts In the Development Of Medical Marijuana Laws
COLORADO SPRINGS, Colo.--(BUSINESS WIRE)-- Cannabis Science Inc. (OTCBB: CBIS) an emerging pharmaceutical cannabis company is very pleased to announce that has added four prominent attorneys, who specialized in marijuana-related cases, to its Policy Advisory Board, as medical marijuana legalization moves closer with President Obama's New Medical Marijuana Policies and initiatives.
Cannabis Science Inc., President & CEO, Dr. Robert Melamede Ph.D., stated, "We will continue to add teams of industry experts to our Company. We are honored that our Policy Advisory Board is expanding with some of the nation's top medical marijuana attorneys. Obviously, we are operating in an area where the laws are evolving very rapidly, and we are pleased to have so many experienced attorneys on board, helping steer the company through these complex and evolving opportunities for us. More professionals will be added who are expert in other relevant fields, such as FDA procedures and state and federal laws. These new outstanding additions to the CBIS team will provide the Company with an expanded base of knowledge to build on. As noted yesterday, the new policy means that state compliant intrastate research in Colorado, California and other states with medical marijuana laws are now protected from federal prosecution."
The four new additions to the Cannabis Science Policy Advisory Board
Robert Raich
Robert A. Raich practices law in Oakland, California, and is a graduate of Harvard University and the University of Texas School of Law. He is one of the most respected attorneys in the area of medical marijuana. He is General Counsel of the Oakland Cannabis Buyers' Cooperative, and was one of the attorneys in the U.S. Supreme Court case, United States v. Oakland Cannabis Buyers' Coop. and another federal medical cannabis case. He is a member of the California Attorney General's Medical Marijuana Task Force (Chairman, Caregiver Issues Subcommittee).
Sean T. McAllister
Sean T. McAllister is a public interest attorney with offices in Denver and Summit County. Sean has been involved with drug policy reform efforts for over a decade. He serves as the Chair of the Board of Directors of Sensible Colorado. Sean is a lifetime member of the NORML Legal Committee. He is a member and Board member of the Colorado Criminal Defense Bar. He helped start the Colorado Bar Association Criminal Sentencing Project in 2005 to focus on criminal justice and drug policy reform. Recently, Sean was appointed to the Governor's Drug Policy Task Force, which is working on reducing drug-sentencing laws to save the state money while maintaining public safety. Along with Brian Vicente, Sean recently founded the Canna-Business Institute designed to educate dispensary owners and caregivers on how to legally operate medical marijuana businesses in Colorado.
Warren Edson
Warren Edson is an experienced criminal defense lawyer in Colorado, having taken part in over 1,000 trials. He is also one of the organizers of Colorado's Medical Marijuana Law, Amendment 20, and is a Lifetime Member, NORML Legal Committee, and is a member, Colorado Criminal Defense Bar, and the National Association of Criminal Defense Lawyers, and is a Board Member, Colorado NORML.
Robert J. Corry, Jr.
Robert J. Corry, Jr. is a Denver-based civil rights and criminal defense attorney, specializing in medical marijuana, who has successfully litigated several high profile cases around the country. He is admitted to the bars of Colorado, California, and Washington, D.C., federal courts in these jurisdictions, as well as the U.S. Supreme Court. Mr. Corry earned his law degree from Stanford University.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.